Search Results - "Roubec, J"

Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months by Grygárková, I, Kolek, V, Skřičková, J, Pešek, M, Zatloukal, P, Salajka, F, Roubec, J, Sixtová, D, Koubková, L, Hejduk, K

Get full text

Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival by Kolek, V, Grygárková, I, Chalupa, J, Koubková, L, Janásková, T, Roubec, J, Popelková, P, Bártek, T, Sixtová, D, Pavlíková, E, Vlásek, T, Chaloupka, F, Skřičková, J

Get full text

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04) by Dy, G.K., Cho, B.C., Oliveira, J., Isla Casado, M.D., Blasco Cordellat, A., Zemanova, M., Roubec, J., Vila Martinez, L., Charbonnier, L., Soufflet, C., de Castro Carpeño, J.

Get full text

Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study by Leal, T.A., Kotecha, R., Ramlau, R., Zhang, L., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L., Havel, L., Kalmadi, S., Ward, J., Andric, Z., Berghmans, T., Gerber, D.E., Kloecker, G., Panikkar, R., Aerts, J., Delmonte, A., Pless, M., Langer, C.

Get full text

1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study by Kotecha, R., Leal, T.A., Raumlau, R., Zhang, L., Milanowski, J., Cobo Dols, M., Roubec, J., Petruzelka, L.B., Havel, L., Kalmadi, S., Ward, J.P., Andric, Z.G., Berghmans, T., Kloecker, G., Panikkar, R., Aerts, J.G., Pless, M., Greil, R., Akerley, W., Langer, C.J.

Get full text

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial by Pirker, Robert, Prof, Pereira, Jose R, MD, Szczesna, Aleksandra, MD, von Pawel, Joachim, MD, Krzakowski, Maciej, Prof, Ramlau, Rodryg, MD, Vynnychenko, Ihor, MD, Park, Keunchil, Prof, Yu, Chih-Teng, MD, Ganul, Valentyn, Prof, Roh, Jae-Kyung, Prof, Bajetta, Emilio, Prof, O'Byrne, Kenneth, Prof, de Marinis, Filippo, MD, Eberhardt, Wilfried, MD, Goddemeier, Thomas, Dipl Stat, Emig, Michael, MD, Gatzemeier, Ulrich, MD

“…Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in…”
Get full text

LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study by Reinmuth, N., Özgüroğlu, M., Leighl, N.B., Galetta, D., Hacibekiroglu, I., Roubec, J., Sendur, M.A.N., Bria, E., Cicin, I., Grohé, C., Harputluoglu, H., Kilickap, S., Novello, S., Opalka, P., Riccardi, F., Ruseva, R.K., Lang, S., Hodari, M., Donner, N., de Marinis, F.

Get full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) by Chang, A., Manegold, C., Douillard, J.-Y., Malik, R., Giaccone, G., Begbie, S., Jennens, R., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Jakesova, J., Roubec, J., Vanasek, J., Barlesi, F., Bennouna-Louridi, J., Chouaid, C., Robinet, G., Souquet, P.-J., Spaeth, D., Schott, R., Lena, H., Baize, N., Molinier, O., Fuchs, F., Marschner, N., Schuette, W., Syrigos, K., Papandreou, C., Bocskei, C., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Maru, A., Pathak, A., Prasad, S.V.S.S., Kilara, N., Gorijavolu, D., John, S., Amoroso, D., Bajetta, E., Bonetti, A., Maio, M., Passalacqua, R., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Samson-Fernando, M.C., Jassem, J., Koralewski, P., Cebotaru, C., Ganea-Motan, D.E., Ianuli, C.H., Manolescu, I.G., Udrea, A., Burdaeva, O., Filippov, A., Lazarev, S., Tan, Y.O., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Lee, J.-S., Lee, J.S., Shin, S.W., Kim, Y.-C., Chang, G.-C., Goan, Y.-G., Kuo, H.-P., Demir, G., Crawford, J., Giaccone, G., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Wade, J., Camidge, R., Hill, D., Rarick, M., Flynn, P., Savin, M., Richards, D., Dangoor, A., Summers, Y., Rankin, E., Rowley, K., Kristeleit, H., Taylor, P.

“…Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced…”
Get full text

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial by Zatloukal, Petr, Petruželka, Luboš, Zemanová, Milada, Kolek, Vı́tězslav, Skřičková, Jana, Pešek, Miloš, Fojtů, Hana, Grygárková, Ivona, Sixtová, Dimka, Roubec, Jaromı́r, Hořenková, Eva, Havel, Libor, Průša, Petr, Nováková, Leona, Skácel, Tomáš, Kůta, Milan

“…Purpose: This randomized, multicenter, phase III trial was conducted to compare the tolerability of gemcitabine plus cisplatin (GP) vs. gemcitabine plus…”
Get full text

Patient attitude and survival in advanced non-small cell lung cancer (NSCLC): Results of a prospective observational study by Altug, S., Wang, L., Chu, D., Park, K., Hsu, H., Cok, G., Roubec, J., Patil, S., Damyanov, D., Reece, W.

“…Abstract only 7148 Background: A physician’s ability to accurately identify a patient’s attitude toward treatment is critical. The primary objective of this…”
Get full text

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results by Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pesek, M., Spasova, I., Hou, J., Kennedy, S., Herbst, R. S.

“…Abstract only 7016 Background: ZD6474, a once-daily oral agent, targets key signaling pathways in cancer by inhibiting VEGF, EGF and RET receptor tyrosine…”
Get full text

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) by Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., Brennscheidt, U., De Rosa, F., Mueller, B., Von Pawel, J.

“…Abstract only…”
Get full text

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) by Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., Brennscheidt, U., De Rosa, F., Mueller, B., Von Pawel, J.

“…Abstract only…”
Get full text

A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC by Heymach, J. V., Johnson, B. E., Rowbottom, J. A., Fidias, P., Lu, C., Prager, D., Roubec, J., Csada, E., Dimery, I., Herbst, R. S.

“…Abstract only…”
Get full text

O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial by Herbst, R., Johnson, B., Rowbottom, J., Fidias, P., Lu, C., Prager, D., Roubec, J., Csada, E., Dimery, I., Heymach, J.

Get full text

The TULUNG clinical registry by Spelda, S, Skřičková, J, Bortlíček, Z, Hejduk, K, Pešek, M, Zatloukal, P, Kolek, V, Salajka, F, Koubková, L, Tomíšková, M, Grygárková, Y, Havel, L, Hrnčiarik, M, Zemanová, M, Sixtová, D, Roubec, J, Coupková, H, Košatová, K

Get more information